Brainomix, an AI medical imaging company focused on stroke and lung disease, has increased its Series C funding to £18.8 million, approximately $25.4 million, following a £4.8 million extension round.
The extension builds on the £14 million raised in early 2025. Existing investors Parkwalk Advisors and Hostplus, through the IP Group Hostplus Innovation Fund, led the additional financing, while U.S.-based Modi Ventures joined as a new investor.
Accelerating U.S. Market Expansion
Brainomix plans to use the fresh capital to strengthen its presence in the United States, where it already operates with multiple FDA-cleared imaging solutions. The funding will support wider adoption of its AI platforms across American hospitals and healthcare systems.
The company’s Brainomix 360 Stroke platform uses artificial intelligence to analyze brain scans in acute stroke cases, helping clinicians make faster and more accurate treatment and transfer decisions. By providing automated imaging insights throughout the patient pathway, the system is designed to improve time-critical care.
Its second core product, e-Lung, applies AI-driven analysis to CT scans to help clinicians detect and track fibrosing lung diseases. The platform aims to support earlier diagnosis and more consistent long-term monitoring.
Advertisement
Strengthening Clinical Integration
Founded in 2010 as a spinout from the University of Oxford, Brainomix operates across the UK, Ireland, and the United States, with customers in more than 20 countries.
CEO and co-founder Dr. Michalis Papadakis emphasized that stroke treatment requires rapid intervention, while lung fibrosis care depends on early identification and ongoing assessment. He noted that the new funding will enhance customer support and facilitate deeper integration of Brainomix’s technology into clinical workflows across the U.S. and Europe.
Modi Ventures’ founder Sahir Ali highlighted the company’s clinical validation and real-world evidence, pointing to improvements in treatment rates and reduced delays in stroke care, as well as the potential of e-Lung to advance earlier detection of fibrosing lung conditions.
About Brainomix
Brainomix develops AI-based imaging software that converts routine medical scans into actionable clinical insights. Focused on stroke and lung disease, the company aims to improve diagnostic accuracy, speed up treatment decisions, and support precision medicine in hospitals worldwide.
